bioAffinity Technologies, Inc.
BIAF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.03 | -0.01 | 0.74 |
| FCF Yield | -66.53% | -47.13% | -59.61% | -3.35% |
| EV / EBITDA | -1.37 | -1.52 | 0.71 | -32.35 |
| Quality | ||||
| ROIC | -218.48% | -124.25% | -35.52% | 577.94% |
| Gross Margin | 36.09% | 31.26% | 90.28% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.76 | 0.50 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,149.16% | – | – | – |
| Free Cash Flow Growth | -21.17% | -41.25% | -109.41% | 7.31% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 0.16 | 1.99 | -4.54 |
| Interest Coverage | -96.82 | -214.76 | -1.58 | -2.20 |
| Efficiency | ||||
| Inventory Turnover | 216.71 | 94.19 | 0.08 | 0.00 |
| Cash Conversion Cycle | -14.13 | -5.91 | -264,552.43 | -17,458.70 |